U.S., Sept. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07168161) titled 'BDB-001 Phase III Trial in ANCA-Associated Vasculitis' on Sept. 04.
Brief Summary: The primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab
Study Start Date: Sept. 29
Study Type: INTERVENTIONAL
Condition:
ANCA Associated Vasculitis (AAV)
Intervention:
DRUG: BDB-001 injection
Intravenously administered
DRUG: Cyclophosphamide
Intravenously administered
BIOLOGICAL: Rituximab
Intravenou...